GY036 A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

  • Phase III
  • Trial Category: Gynecologic

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Nebraska Methodist Estabrook Cancer Center

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*